Archives: Agenda

Most Sponsors and CROs have made the move to RBQM at an operational level – but is the approach actually intelligent, or is it still driven by manual review cycles, static risk thresholds and teams buried in reporting?

• Moving from operational RBQM to AI-enabled RBQM that learns, adapts and surfaces the right signals before they become issues
• Identifying where operational RBQM is still leaving value on the table and where AI can create a step change in quality and efficiency
• Examining what the data shows about improvements in speed, accuracy and cost
• Achieving real-time inspection readiness for Sponsors and building a quality capability that helps CROs win and retain business

• Understanding how the new UK framework is working in practice 6 months after implementation
• Identifying key operational changes, including approvals, consent, and trial setup
• Clarifying how sponsors can take advantage of faster pathways while staying compliant

• Exploring the meaning of risk sharing across roles
• Supporting balance between procurement and R&D priorities
• Strengthening partnership models through transparency

Moderator

Alexander Booth, Host, Lab to Lives Podcast

1 x Vendor panel seat available

• Comparing timelines and setup across the UK EU and other key regions
• Understanding trade-offs between speed cost quality and patient access
• Deciding how to prioritise regions based on trial type and strategy

Moderator

Tina Karunaratne, Founder and President, Bridge to Compassionate Care

Panelists

Lene Grejs Petersen, Senior EU CT-policy adviser, Danish Medicines Agency

Tanya Turgoose, Industry Operations Manager, NIHR UK Clinical Research Facilities (UKCRF) Network

1 x Biopharma panel seat available

1 x Vendor panel seat available